DiscoverThe Lancet Respiratory Medicine in conversation withToby Maher on ENV-101 in patients with idiopathic pulmonary fibrosis
Toby Maher on ENV-101 in patients with idiopathic pulmonary fibrosis

Toby Maher on ENV-101 in patients with idiopathic pulmonary fibrosis

Update: 2025-09-28
Share

Description

Toby Maher joins us to discuss results of a randomised, double-blind, placebo-controlled, proof-of-concept trial of ENV-101, an oral inhibitor of the hedgehog signalling pathway, in patients with idiopathic pulmonary fibrosis.

Read the full article:

https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(25)00239-5/fulltext?dgcid=buzzsprout_icw_podcast_September_25_lanres

Continue this conversation on social!
Follow us today at...
https://thelancet.bsky.social/
https://instagram.com/thelancetgroup
https://facebook.com/thelancetmedicaljournal
https://linkedIn.com/company/the-lancet
https://youtube.com/thelancettv

Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Toby Maher on ENV-101 in patients with idiopathic pulmonary fibrosis

Toby Maher on ENV-101 in patients with idiopathic pulmonary fibrosis

The Lancet Group